| Literature DB >> 24169342 |
K B Dieperink1, C Johansen, S Hansen, L Wagner, K K Andersen, L R Minet, O Hansen.
Abstract
BACKGROUND: The objective of this study is the effectiveness of multidisciplinary rehabilitation on treatment-related adverse effects after completed radiotherapy in patients with prostate cancer (PCa).Entities:
Mesh:
Substances:
Year: 2013 PMID: 24169342 PMCID: PMC3859951 DOI: 10.1038/bjc.2013.679
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Figure 1CONSORT-Flow chart. .
Figure 2Graphical depiction of the intervention in a randomised rehabilitation study with 161 participants with PCa, Odense, Denmark. .
Socio-demographic and biological pre-intervention characteristics of 161 participants and 48 refusers with primary prostate cancer included in a randomised controlled trial after radiotherapy and androgen deprivation therapy, 2010–2012 Odense, Denmark
| Age at first radiotherapy date (years), mean (s.d.) | 68.2 (4.8) | 69.0 (5.2) | 68.7 (6.4) |
| Weight (kilo) reported at pre-intervention mean (s.d.) | 84.7 (12.7) | 86.3 (14.8) | 85.9 (15.6) |
| Unknown | 1 | 3 | 7 |
| Body mass index (BMI) kg m−2 mean (s.d.) | 27.1 (3.6) | 27.4 (4.1) | 27.2 (4.6) |
| Unknown | 1 | 3 | 7 |
| Living alone | 10 (13%) | 12 (15%) | 8 (19%) |
| Living with a spouse | 68 (87%) | 67 (85%) | 33 (81%) |
| Unknown | 1 | 3 | 7 |
| 9–10 | 31 (40%) | 36 (46%) | 21 (52%) |
| 12–13 | 24 (31%) | 23 (29%) | 12 (30%) |
| 13–16 | 18 (23%) | 18 (23%) | 6 (15%) |
| 18–20 | 5 (6%) | 2 (2%) | 1 (3%) |
| Unknown | 1 | 3 | 8 |
| Never smoker | 33 (42%) | 32 (41%) | 12 (29%) |
| Past smoker | 30 (39%) | 35 (44%) | 20 (49%) |
| Current smoker | 15 (19%) | 12 (15%) | 9 (22%) |
| Unknown | 1 | 3 | 7 |
| PSA pre-treatment serum mean ng ml−1 (s.d.) | 21.5 (17.7) | 19.8 (16.8) | 21.6 (18.4) |
| <7 | 10 (13%) | 17 (21%) | 10 (21%) |
| 7 | 47 (59%) | 44 (54%) | 25 (52%) |
| >7 | 22 (28%) | 21 (25%) | 13 (27%) |
| T1 | 8 (10%) | 9 (11%) | 6 (12%) |
| T2 | 34 (44%) | 35 (43%) | 23 (48%) |
| T3 | 36 (46%) | 38 (46%) | 19 (40%) |
| Unknown | 1 | | |
| Low | 1 (1%) | 3 (4%) | 6 (12%) |
| Intermediate | 19 (24%) | 13 (16%) | 8 (17%) |
| High | 59 (75%) | 65 (80%) | 34 (71%) |
| Unknown | | 1 | |
| No | 3 (4%) | 2 (3%) | 5 (11%) |
| Androgen deprivation therapy (ADT) | 76 (96%) | 79 (97%) | 42 (89%) |
| Unknown | | 1 | 1 |
| Charlson index score 1 | 20 (25%) | 19 (23%) | 13 (27%) |
| Score 2 | 4 (5%) | 5 (6%) | 1 (2%) |
| Score 3 | 0 | 0 | 0 |
| Score 6 | 0 | 0 | 0 |
Abbreviation: PSA=prostate-specific antigen values.
Fisher's exact test P=0.028
Fisher's exact test P=0.049
Mean changes in QoL scores among 161 Danish prostate cancer survivors included in a randomised rehabilitation study, Odense, Denmark
| Physical QoL (PCS) | 3.6 | 1.3; 5.8 | 0.002 |
| Mental QoL (MCS) | 0.7 | −1.6; 3.0 | 0.549 |
| Urinary | 4.5 | 0.6; 8.4 | 0.023 |
| Incontinence | 2.6 | −1.8; 6.9 | 0.242 |
| Irritative | 5.8 | 1.4; 10.3 | 0.011 |
| Bowel | 3.0 | −1.9; 8.0 | 0.224 |
| Sexual | 3.6 | −0.9; 8.0 | 0.117 |
| Hormonal | 4.8 | 0.8; 8.8 | 0.018 |
Abbreviations: CI=95% confidence interval; EPIC=Expanded Prostate Cancer Index Composite; MCS=Mental Component Summary; PCS=Physical Component Summary; QoL=quality of life.
Multiple linear regression analysis adjusted for pre-intervention scores.
Reported P-values are two-sided and P<0.05 was considered statistically significant.
Example: if the patient is in the intervention group, his mean QoL score (0–100 scale) regarding urinary irritative sum-score increases with 5.8 point compared with the controls.
Pre-intervention level and changes in disease-specific QoL scores (EPIC), and general QoL scores (SF-12) in intervention and control groups at 4 weeks (pre-intervention) and 24 weeks after radiotherapy (post intervention) among 161 survivors with primary prostate cancer included in (RePCa) a prospective randomised rehabilitation study, 2010–2012 Odense, Denmark
| | |||||
| Mean (s.d.) | 4 Weeks after radiotherapy | Between follow-up and pre-intervention | 4 Weeks after radiotherapy | Between follow-up and pre-intervention | Cohen's |
| Urinary irritative | 67.7 (18.7) | 17.6 (18.1) | 68.1 (18.7) | 11.6 (16.5) | 0.40 |
| Urinary incontinence | 82.5 (17.5) | 7.3 (14.9) | 82.2 (21.7) | 4.9 (15.8) | |
| Urinary sum-score | 73.5 (14.5) | 13.3 (13.9) | 73.1 (17.4) | 9.0 (12.9) | 0.34 |
| Bowel sum-score | 77.6 (19.9) | 9.7 (20.3) | 77.0 (20.0) | 7.6 (16.4) | |
| Sexual sum-score | 15.0 (19.5) | −1.3 (13.7) | 14.0 (20.1) | −4,1 (16.4) | |
| Hormonal sum-score | 71.6 (18.8) | 2.3 (13.2) | 72.8 (18.9) | −2.8 (12.8) | 0.19 |
| PCS | 47.4 (8.3) | 1.9 (6.7) | 47.5 (9.0) | −1.7 (7.9) | 0.35 |
| MCS | 53.0 (8.7) | 2.3 (7.1) | 51.7 (9.6) | 2.3 (8.9) | |
Abbreviations: EPIC=Expanded Prostate Cancer Index Composite; MCS=Mental Component Summary; PCS=Physical Component Summary; QoL=quality of life; SF-12=Short-form-12.
Higher scores indicating better QoL. Note: SF-12 is standardised to the population normative values of the United States of America , with a mean score of 50 and a s.d. of 10.
Cohen's d effect size=group mean differences at patients post intervention divided by mean s.d.
Figure 3Box-plot median urinary irritative sum-score post intervention in a randomised rehabilitation study with 161 participants with PCa, Odens, Denmark. The whiskers show the lower/upper adjacent value and the box shows 25th–75th percentile. The dots show outliers.
Pelvic floor muscle strength in prostate cancer patients treated with radiotherapy in RePCa: a randomised controlled rehabilitation study
| | ||||||
|---|---|---|---|---|---|---|
| No. of participants | | |||||
| Digital evaluation | 4.0 (3.8;4.1) | 3.8 (3.5;4.0) | 3.9 (3.6;4.1) | 3.8 (3.6;4.1) | 3.7 (3.5;4.0) | NS |
| Static strength no. of seconds to hold one contraction | 34.4 (31.1;37.7) | 35.2 (30.2;40.2) | 36.1 (31.0;41.2) | 31.6 (26.6;36.6) | 32.9 (28.0;37.8) | NS |
| Dynamic strength no. of contractions during 60 s | 22.2 (19.9;24.5) | 21.2 (17.7;24.7) | 22.7 (18.9;26.5) | 19.1 (15.9;22.3) | 19.2 (15.9;22.6) | NS |
| No. of participants | | |||||
| EMG average activity (μV) | 38.2 (34.8;41.6) | 31.3 (27.9;34.8) | 24.7 (21.7;27.7) | 31.6 (27.3;35.9) | 23.3 (20.4;26.2) | NS |
| EMG average rest (μV) | 6.8 (6.2;7.5) | 5.8 (5.0;6.6) | 4.8 (4.0;5.5) | 5.5 (4.9;6.1) | 4.9 (3.6;6.2) | NS |
Abbreviations: CI=class interval; EMG=electromyography.
Post-intervention differences between groups. Wilcoxon Sign-rank test. Reported P-values are two-sided and P<0.05 was considered statistically significant.
Measured by Modified Oxford Scale 0–6.